Since fibrosis is the most compelling predictor of outcomes, current and future therapies must focus on improving fibrosis by indirectly reducing pro-fibrotic inflammatory signaling or directly abrogating fibrosis
Trikafta/Kaftrio (elexacaftor/tezacaftor/ivacaftor) Disease area(s): Respiratory/rare disease Manufacturer(s): Vertex Pharmaceuticals Incorporated 2024 Sales (USD): $10.24 billion Why it sold so well: Trikafta (marketed as Kaftrio outside the US), a combination therapy of elexacaftor, tezacaftor and ivacaftor, was the primary driver of Vertex Pharmaceuticals strong commercial performance in 2024
For example, if you are allergic to an inactive ingredient of semaglutide, you can get an allergen-free medication dispensed from a compounding pharmacy
How moringa and berberine work together to stimulate GLP-1 naturally, improve insulin sensitivity, and support sustainable weight loss
Sustainable progress matters: The goal is not quick, temporary results